Finasteride as a Chemopreventive Agent in Prostate Cancer.

The PCPT has shown finasteride to be an effective chemopreventive causal agent in low-grade prostate malignant neoplastic disease. Interest for its widespread use has been tempered by the reported amount in high-grade cancers in low-risk men who had taken the drug. Recent studies seem to suggest that finasteride causes a spotting bias in biopsy specimens, due mainly to its validness on prostate bulk. Time to come substance from both further analyses of the PCPT and from the results of the ongoing REDUCE endeavour will be helpful in clarifying the chemopreventive role of 5-alpha reductase inhibitors. In arithmetic operation, questions such as economic property, dose and dose agenda, and whether dutasteride is more effective than finasteride need to be answered before widespread use of these drugs as post chemopreventive agents in prostate Cancer.